IBD is a recurrent inflammation of the gastrointestinal tract caused by an abnormal immune response to gut microbiota. It is a genetically predisposed condition, with incidence rates ranging from 4 to 10 per 100,000 people annually. It is more prevalent in highly industrialized countries and affects the entire bowel wall. Both forms are categorized by their location and degree of involvement. IBD is characterized by diffuse inflammation of the intestinal mucosa, proctitis, and transmural ulceration. Treatment focuses on immunosuppressive drugs and anti-inflammatory compounds, but achieving remission remains a clinical challenge. A 23-year-old female patient with pat history of Arthritis was admitted to the hospital. She complained of weight loss (lost about 5 – 10 kg in the last month), diminished appetite, weakness, blood in her faeces, and abdominal pain. The patient had significant anaemia and a tentative diagnosis of UGI-bleed. She is married, has a son who is nine years old, has regular bowel and bladder habits. The patient's MCHC was 29.4 g/dl, mean MCV was 72.8 fL, and haemoglobin was 11.1%. The patient's colonoscopy revealed Crohn's disease and colitis with rectal sparing. ANA screening tested positive and Negative for RF-IgM. The Patient’s medication regimen includes Intravenous dextrose, Vitamin supplementation, Magnesium sulphate, tranexamic acid, Metronidazole, Cefoperazone & Sulbactam, and Pantoprazole. The oral supplementations include Syrup Sucralfate, probiotic capsule, Tab. Hydroxychloroquine, Tab. Tramadol & Acetaminophen, Mesalamine in tablet and sachet usually taken by mixing in water.